Beckman Coulter Creates a CE Mark for the MDW-SARS CoV-2 Application as an Aid in Identifying Patients With a Risk of COVID-19 in A&E

Beckman Coulter Creates a CE Mark for the MDW-SARS CoV-2 Application as an Aid in Identifying Patien ...

Beckman Coulter''s MDW-SARS CoV-2 application has received the CE Mark for its MDW application as an aid in identifying adult patients with the risk of SARS-CoV-2 viral infection when presented to the Accident & Emergency department (A&E).

The MDW (Monocyte Distribution Width) is a measure of increased morphological variability of monocytes in response to bacterial, viral, or fungal infections. This is an in vitro diagnostic parameter that is usually requested in A&E. MDW is the only proprietary, regulatory-cleared haematological biomarker exclusively to Beckman Coulter analyses that can assist in determining the risk of severe infection and sepsis in adult patients.

Several influential European studies have shown an increase in MDW in COVID-19 patients.[1][2] These studies have shown that MDW is significantly higher in COVID-19 patients than those without, thus indicating that an upfront MDW measurement while awaiting SARS-CoV-2 molecular findings may assist in rapid differential diagnosis in emergency settings.[5] The observations bolster the evidence that COVID-19 is a multi-organ disease that has resulted in increased response in pro-inflammatory cytok

The morphology of monocytes changes when the immune system activates a stimulus, such as in cases of viral or bacterial infections, according to Tommaso Trenti, the director of the Laboratory Medicine Department in Modena, Italy. I am extremely pleased that our centre was able to assist confirm the role of this new test, which now has the CE mark approval for IVD devices, which means it can now be used on COVID-19 patients.

The MDW-SARS CoV-2 is a highly sensitive test (87%) with a high NPV (96%). It allows physicians to perform more accurate risk assessment of COVID-19 for patients for whom RT-PCR data is not available or contradicts clinical presentation, thus giving the clinicians greater choice on patient location in A&E.

In the first study published in Clinica Chimica Acta, the MDW results already considered to be helpful for COVID-19 patients, both because of their speed and how quickly it could be obtained. The monocyte population is the first component to be involved in the immune response to COVID-19, which can therefore be combined with a simple CBC. The aggressiveness of the virus and the reactive state of the patient were discovered to be connected to the MDW parameter, which is a significant step forwards.

Both Beckman CoulterDxH 900 andDxH 690T haematology analysers are available for testing and testing, according to a CBC-DIFF. For additional information, visit the company''s website:http://www.beckmancoulter.com/mdw.

You may also like: